检索结果 - Levy, Elliott

Combination of PARP inhibitor olaparib, and PD-L1 inhibitor durvalumab, in recurrent ovarian cancer: a proof-of-concept phase 2 study 由 Lampert, Erika J., Zimmer, Alexandra, Padget, Michelle, Cimino-Mathews, Ashley, Nair, Jayakumar, Liu, Yingmiao, Swisher, Elizabeth M., Hodge, James W., Nixon, Andrew B., Nichols, Erin, Bagheri, Mohammad H., Levy, Elliott, Radke, Marc R., Lipkowitz, Stanley, Annunziata, Christina M., Taube, Janis M., Steinberg, Seth M., Lee, Jung-Min

获取全文 获取全文 获取全文